SmileDirectClub shares tank as much as 20% after first earnings report since IPO fails to impress

Health, Fitness & Food

Jordan Katzman, co-founder of SmileDirectClub Inc., center, and Alex Fenkell, co-founder of SmileDirectClub Inc., right, look at a monitor during the company’s initial public offering (IPO) at the Nasdaq MarketSite in New York, Sept. 12, 2019.

Bloomberg | Bloomberg | Getty Images

Shares of SmileDirectClub tanked by as much as 20% in midday trading Wednesday, following the company’s first earnings report since going public in September.

The company, which sells teeth aligners directly to consumers, reported a loss of 89 cents per share on revenue of $180.2 million after the markets closed Tuesday. Wall Street expected revenue of $165.4 million, according to analysts polled by Refinitiv.

Its guidance for fourth-quarter earnings fell short of analysts’ estimates, raising questions about the company’s ability to manage investor expectations. Investors also question whether or not it will be able to generate $1.2 billion in revenue next year as expected, given its current growth rate, analysts led by Glen Santangelo at Guggenheim said in a research note to investors Wednesday.

SmileDirectClub’s legal expenses doubled in the quarter from the same time last year, due to pending legislation that could impose harsher regulations on online dentistry companies.

The company made its public debut Sept. 12, and saw its shares plummet 28% in its first day of trading. The poor public debut marked SmileDirectClub as the worst IPO of a “unicorn” company this year, or start-up valued more than $1 billion.

The company’s shares are down approximately 60% off its initial IPO price of $23 per share.

Products You May Like

Articles You May Like

How Canada is fighting Covid-19: Ramping up PPE production, travel ban from the U.S. and Bonnie Henry
WHO warns the coronavirus is ‘getting worse,’ continues to accelerate
New York City public schools won’t fully reopen for its 1.1 million students this fall, Mayor de Blasio says
Gilead says remdesivir coronavirus treatment reduces risk of death in severely sick patients
Bill Gates warns against coronavirus vaccine going to highest bidder — ‘We’ll have a deadlier pandemic’

Leave a Reply

Your email address will not be published. Required fields are marked *